Agios Pharmaceuticals, Inc. Overview
Pro stress-test →Agios Pharmaceuticals is a commercial-stage biopharmaceutical company pioneering therapies for genetically defined rare diseases, with a core focus on cellular metabolism and pyruvate kinase (PK) activation. The company achieved a historic milestone with the 2025 U.S. FDA approval of AQVESME (mitapivat) for thalassemia, marking the first disease-modifying therapy for this blood disorder.
Strategic Profile
Pro stress-test →Agios positions itself as the leader in PK activation with a growing pipeline addressing high-value rare disease indications including sickle cell disease, myelodysplastic syndromes, and other hemolytic anemias. The company leverages deep expertise in cellular metabolism and strong partnerships with patient communities to drive differentiated product development and commercialization.
Competitive Landscape
Pro stress-test →Agios competes in the rare disease and hematology treatment space against companies like Vicore Pharma Holding and others pursuing hemolytic anemia and genetic disease therapies. Its differentiated position stems from proprietary expertise in pyruvate kinase activation and established first-mover advantage with AQVESME/PYRUKYND in thalassemia.
Industry Context
Agios Pharmaceuticals, Inc. operates in Biopharmaceutical/Rare Diseases.
Key facts
Founded: 2007 · Headquarters: Cambridge, Massachusetts · Employees: 488 · Revenue: $44.8M · Market cap: $1.57B